Cause and management of heart failure in patients with chronic renal disease

Seminars in Nephrology

Volumn 21, Issue 1, 2001, Pages 3-12

  Al Ahmad, Amin ^a,b,c   Sarnak, Mark J ^a,b,c   Salem, Deeb N ^a,b,c   Konstam, Marvin A ^a,b,c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HOMOCYSTEINE; HYDRALAZINE; LIPID; LOOP DIURETIC AGENT; LOSARTAN; NITRATE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIALYSIS; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL; UREMIA;

EID: 0035132108     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1053/snep.2001.18367     Document Type: Article

References (84)

1. Special report, controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here?
2. Epidemiology of cardiac disease in dialysis patients
3. The clinical epidemiology of cardiac disease in chronic renal failure
4. Clinical epidemiology of cardiovascular disease in chronic renal disease
5. The outcome and risk factors for left ventricular disorders in chronic uremia
6. Long-term evolution of cardiomyopathy in dialysis patients
7. Analysis of left-ventricular changes associated with chronic hemodialysis. A noninvasive follow-up study
8. Outcome and risk factors of ischemic heart disease in chronic uremia
9. Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors
10. Cardiac disease in the diabetic dialysis patient
11. Poor long term survival after acute myocardial infarction among patients on long term dialysis
12. Blood pressure and end-stage renal disease in men
13. Blood pressure, left ventricular hypertrophy and long term prognosis in hemodialysis patients
14. Volume sensitivity of blood pressure in end-stage renal disease
15. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease
16. Alterations in diastolic function in response to progressive left ventricular hypertrophy
17. Impact of left ventricular hypertrophy on survival in end-stage renal disease
18. 1992 Annual Report: IV. Comorbid conditions and correlations with mortality risk among 3,399 incident hemodialysis patients
19. "U" curve association of blood pressure and mortality in hemodialysis patients
20. Lipoprotein (a) in renal disease
21. Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional risk factors
22. Plasma homocyst(e)ine levels in men with premature coronary artery disease
23. Hyperhomocysteinemia in chronic renal disease
24. Elevated fasting total homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study
25. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes
26. Renal disorders and heart disease
27. High-output cardiac failure due to hemodialysis arteriovenous fistula
28. Clinical problem solving. High on the differential
29. High-output cardiac failure due to excessive shunting in a hemodialysis access fistula: An easily overlooked diagnosis
30. Cardiac failure and upper extremity arteriovenous dialysis fistulas: Case reports and a review of the literature
31. Uremic cardiomyopathy - Effect of hemodialysis on left ventricular function in end-stage renal failure
32. Effect of hemodialysis on left ventricular function, dissociation of changes in filling volume and in contractile state
33. Left ventricular diastolic function in end-stage renal disease and the impact of hemodialysis
34. Effects of hemodialysis on left ventricular filling
35. Left ventricular morphology and diastolic function in uremia: Echocardiographic evidence of a specific cardiomyopathy
36. Abnormal diastolic left ventricular filling by pulsed doppler echocardiography in patients on continuous ambulatory peritoneal dialysis
37. Cardiac disease in chronic uremia: Pathogenesis
38. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease
39. Cardiac function and hematocrit level
40. Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin
41. Cardiovascular consequences of renal anaemia and erythropoietin therapy
42. The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - The experience of the Lombardy dialysis registry
43. Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin
44. Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients
45. Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients
46. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
47. Increased ionized calcium and left ventricular contractility during hemodialysis
48. Cardiac disease in chronic uremia: Uremia related risk factors
49. Cardiac depressant factors in renal disease
50. Parathyroid hormone, vitamin D and cardiovascular disease in chronic renal failure
51. Cardiac disease in chronic uremia: Pathophysiology
52. Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic hemodialysis patient: A national study
53. Impairment of cardiac function and energetics in experimental renal failure
54. The heart in uremia
55. Diffuse intermyocardiocytic fibrosis in uremic patients
56. The role of parathyroidhormone in the genesis of interstitial cell activation in uremia
57. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations
58. Cardiac disease in chronic uremia: Management
59. Choice of ESRD treatment strategy according to cardiac status
60. Options in dialysis therapy: Significance of cardiovascular findings
61. Comparative mortality of hemodialysis and peritoneal dialysis in Canada
62. The use of peritoneal dialysis in special situations
63. Influence of fluid removal rate during hemodialysis on left ventricular performance and exercise tolerance in patients with coronary artery disease
64. Myocardial perfusion and left ventricular performance during long and short haemodialysis in patients with coronary artery disease
65. Management of heart failure: I. Pharmacologic treatment
66. Drug therapy: The management of chronic heart failure
67. Heart failure society guidelines for the management of patients with heart failure due to left ventricular systolic dysfunction-pharmacolgic approaches
68. Drug therapy: Diuretic therapy
69. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
70. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
71. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandanavian Enalapril Study (CONSENSUS)
72. Effects of an agiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patents. The Heart Outcomes Prevention evaluation Study Investigators
73. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease: Comparative effects of ACE inhibition and calcium channel blockade
74. Renoprotective benefits of RAS inhibition: From ACEI to angiotension II antagonists
75. Effect of vasodilator therapy on mortality in chronic congestive heart failure: A result of a Veteran Administration Cooperative Study (V-HeFT)
76. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The losartan heart failure survival study ELITE II
77. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
78. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
79. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)
80. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: Results of the PROVED trial. PROVED investigation group
81. Withdrawal of digoxin from patients with chronic heart failure treated with angiotension-converting-enzyme inhibitors
82. The effect of digoxin on mortality and morbidity in patients with heart failure. The digitalis investigation group
83. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators